These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29162604)

  • 1. Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1.
    Chen K; Wu Q; Hu K; Yang C; Wu X; Cheung P; Williams KJ
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):102-113. PubMed ID: 29162604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.
    Hassing HC; Mooij H; Guo S; Monia BP; Chen K; Kulik W; Dallinga-Thie GM; Nieuwdorp M; Stroes ES; Williams KJ
    Hepatology; 2012 Jun; 55(6):1746-53. PubMed ID: 22234891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins.
    Fischer AW; Albers K; Krott LM; Hoffzimmer B; Heine M; Schmale H; Scheja L; Gordts PLSM; Heeren J
    Mol Metab; 2018 Oct; 16():88-99. PubMed ID: 30100244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins.
    Chen K; Liu ML; Schaffer L; Li M; Boden G; Wu X; Williams KJ
    Hepatology; 2010 Dec; 52(6):1957-67. PubMed ID: 21049473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats.
    Qin B; Anderson RA; Kuzuya T; Kitaura Y; Shimomura Y
    Atherosclerosis; 2012 Jun; 222(2):409-16. PubMed ID: 22546076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants.
    Tirronen A; Vuorio T; Kettunen S; Hokkanen K; Ramms B; Niskanen H; Laakso H; Kaikkonen MU; Jauhiainen M; Gordts PLSM; Ylä-Herttuala S
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2327-2337. PubMed ID: 30354205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice.
    Stanford KI; Bishop JR; Foley EM; Gonzales JC; Niesman IR; Witztum JL; Esko JD
    J Clin Invest; 2009 Nov; 119(11):3236-45. PubMed ID: 19805913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.
    Gonzales JC; Gordts PL; Foley EM; Esko JD
    J Clin Invest; 2013 Jun; 123(6):2742-51. PubMed ID: 23676495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants.
    Anower-E-Khuda F; Singh G; Deng Y; Gordts PLSM; Esko JD
    Glycobiology; 2019 Jul; 29(8):582-592. PubMed ID: 31094413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic syndecan-1 changes associate with dyslipidemia after renal transplantation.
    Adepu S; Katta K; Tietge UJ; Kwakernaak AJ; Dam W; van Goor H; Dullaart RP; Navis GJ; Bakker SJ; van den Born J
    Am J Transplant; 2014 Oct; 14(10):2328-38. PubMed ID: 25154787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor.
    Chen K; Williams KJ
    J Biol Chem; 2013 May; 288(20):13988-13999. PubMed ID: 23525115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance.
    Deng Y; Foley EM; Gonzales JC; Gordts PL; Li Y; Esko JD
    Hepatology; 2012 Jan; 55(1):277-86. PubMed ID: 21898481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance.
    Laatsch A; Merkel M; Talmud PJ; Grewal T; Beisiegel U; Heeren J
    Atherosclerosis; 2009 May; 204(1):105-11. PubMed ID: 18834984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association.
    Tomiyama A; Uekita T; Kamata R; Sasaki K; Takita J; Ohira M; Nakagawara A; Kitanaka C; Mori K; Yamaguchi H; Sakai R
    Cancer Res; 2014 Jul; 74(14):3790-801. PubMed ID: 24830726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syndecan-1 inhibits early stages of liver fibrogenesis by interfering with TGFβ1 action and upregulating MMP14.
    Regős E; Abdelfattah HH; Reszegi A; Szilák L; Werling K; Szabó G; Kiss A; Schaff Z; Kovalszky I; Baghy K
    Matrix Biol; 2018 Aug; 68-69():474-489. PubMed ID: 29454902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival.
    Zhang Y; Li J; Song Y; Chen F; Pei Y; Yao F
    Mol Med Rep; 2014 Aug; 10(2):860-6. PubMed ID: 24913320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts.
    Fuki IV; Meyer ME; Williams KJ
    Biochem J; 2000 Nov; 351 Pt 3(Pt 3):607-12. PubMed ID: 11042114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
    Chan DC; Wong AT; Yamashita S; Watts GF
    Atherosclerosis; 2012 Apr; 221(2):484-9. PubMed ID: 22341868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic deficiency of Poldip2 in type 2 diabetes dampens lipid and glucose homeostasis.
    Jiang Z; Zhou J; Li T; Tian M; Lu J; Jia Y; Wan G; Chen K
    Metabolism; 2019 Oct; 99():90-101. PubMed ID: 31351995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.